Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GS1-144 Tablets for Moderate to Severe Vasomotor Symptoms in Postmenopausal Women (Phase II)
ChiCTR2400090826Phase 2Not yet recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of GS1-144 in menopause (4 arms), sponsored by Peking Union Medical College Hospital. Primary endpoints: Change in frequency of moderate to severe vasomotor symptoms from baseline at Week 12 and Change in severity of moderate to severe vasomotor symptoms from baseline at Week 12. Planned start Oct 2024; status: not yet recruiting.
02
Drugs
GS1-144
03
Conditions
menopause
Beyond the preview
Go deeper on ChiCTR2400090826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400090826.